Targeting of 3D oral cancer spheroids by αVβ6 integrin using near-infrared peptide-conjugated IRDye 680
In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infra...
Saved in:
| Published in: | Cancer cell international Vol. 24; no. 1; pp. 228 - 17 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central
29-06-2024
BMC |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infrared fluorescence guided surgery (FGS) could improve surgical resection using fluorescent probes. αVβ6 integrin has shown great potential for cancer targeting due to its overexpression in oral cancers. Red fluorescent contrast agent IRDye 680 coupled with anti-αVβ6 peptide (IRDye-A20) represents an asset to improve FGS of oral cancer. This study investigates the potential of IRDye-A20 as a selective imaging agent in 3D three-dimensional tongue cancer cells.
αVβ6 integrin expression was evaluated by RT-qPCR and Western Blotting in 2D HSC-3 human tongue cancer cells and MRC-5 human fibroblasts. Targeting ability of IRDye-A20 was studied in both cell lines by flow cytometry technique. 3D tumor spheroid models, homotypic (HSC-3) and stroma-enriched heterotypic (HSC-3/MRC-5) spheroids were produced by liquid overlay procedure and further characterized using (immuno)histological and fluorescence-based techniques. IRDye-A20 selectivity was evaluated in each type of spheroids and each cell population.
αVβ6 integrin was overexpressed in 2D HSC-3 cancer cells but not in MRC-5 fibroblasts and consistently, only HSC-3 were labelled with IRDye-A20. Round shaped spheroids with an average diameter of 400 μm were produced with a final ratio of 55%/45% between HSC-3 and MRC-5 cells, respectively. Immunofluorescence experiments demonstrated an uniform expression of αVβ6 integrin in homotypic spheroid, while its expression was restricted to cancer cells only in heterotypic spheroid. In stroma-enriched 3D model, Cytokeratin 19 and E-cadherin were expressed only by cancer cells while vimentin and fibronectin were expressed by fibroblasts. Using flow cytometry, we demonstrated that IRDye-A20 labeled the whole homotypic spheroid, while in the heterotypic model all cancer cells were highly fluorescent, with a negligible fluorescence in fibroblasts.
The present study demonstrated an efficient selective targeting of A20FMDV2-conjugated IRDye 680 in 3D tongue cancer cells stroma-enriched spheroids. Thus, IRDye-A20 could be a promising candidate for the future development of the fluorescence-guided surgery of oral cancers. |
|---|---|
| AbstractList | In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infrared fluorescence guided surgery (FGS) could improve surgical resection using fluorescent probes. αVβ6 integrin has shown great potential for cancer targeting due to its overexpression in oral cancers. Red fluorescent contrast agent IRDye 680 coupled with anti-αVβ6 peptide (IRDye-A20) represents an asset to improve FGS of oral cancer. This study investigates the potential of IRDye-A20 as a selective imaging agent in 3D three-dimensional tongue cancer cells.BACKGROUNDIn the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infrared fluorescence guided surgery (FGS) could improve surgical resection using fluorescent probes. αVβ6 integrin has shown great potential for cancer targeting due to its overexpression in oral cancers. Red fluorescent contrast agent IRDye 680 coupled with anti-αVβ6 peptide (IRDye-A20) represents an asset to improve FGS of oral cancer. This study investigates the potential of IRDye-A20 as a selective imaging agent in 3D three-dimensional tongue cancer cells.αVβ6 integrin expression was evaluated by RT-qPCR and Western Blotting in 2D HSC-3 human tongue cancer cells and MRC-5 human fibroblasts. Targeting ability of IRDye-A20 was studied in both cell lines by flow cytometry technique. 3D tumor spheroid models, homotypic (HSC-3) and stroma-enriched heterotypic (HSC-3/MRC-5) spheroids were produced by liquid overlay procedure and further characterized using (immuno)histological and fluorescence-based techniques. IRDye-A20 selectivity was evaluated in each type of spheroids and each cell population.METHODSαVβ6 integrin expression was evaluated by RT-qPCR and Western Blotting in 2D HSC-3 human tongue cancer cells and MRC-5 human fibroblasts. Targeting ability of IRDye-A20 was studied in both cell lines by flow cytometry technique. 3D tumor spheroid models, homotypic (HSC-3) and stroma-enriched heterotypic (HSC-3/MRC-5) spheroids were produced by liquid overlay procedure and further characterized using (immuno)histological and fluorescence-based techniques. IRDye-A20 selectivity was evaluated in each type of spheroids and each cell population.αVβ6 integrin was overexpressed in 2D HSC-3 cancer cells but not in MRC-5 fibroblasts and consistently, only HSC-3 were labelled with IRDye-A20. Round shaped spheroids with an average diameter of 400 μm were produced with a final ratio of 55%/45% between HSC-3 and MRC-5 cells, respectively. Immunofluorescence experiments demonstrated an uniform expression of αVβ6 integrin in homotypic spheroid, while its expression was restricted to cancer cells only in heterotypic spheroid. In stroma-enriched 3D model, Cytokeratin 19 and E-cadherin were expressed only by cancer cells while vimentin and fibronectin were expressed by fibroblasts. Using flow cytometry, we demonstrated that IRDye-A20 labeled the whole homotypic spheroid, while in the heterotypic model all cancer cells were highly fluorescent, with a negligible fluorescence in fibroblasts.RESULTSαVβ6 integrin was overexpressed in 2D HSC-3 cancer cells but not in MRC-5 fibroblasts and consistently, only HSC-3 were labelled with IRDye-A20. Round shaped spheroids with an average diameter of 400 μm were produced with a final ratio of 55%/45% between HSC-3 and MRC-5 cells, respectively. Immunofluorescence experiments demonstrated an uniform expression of αVβ6 integrin in homotypic spheroid, while its expression was restricted to cancer cells only in heterotypic spheroid. In stroma-enriched 3D model, Cytokeratin 19 and E-cadherin were expressed only by cancer cells while vimentin and fibronectin were expressed by fibroblasts. Using flow cytometry, we demonstrated that IRDye-A20 labeled the whole homotypic spheroid, while in the heterotypic model all cancer cells were highly fluorescent, with a negligible fluorescence in fibroblasts.The present study demonstrated an efficient selective targeting of A20FMDV2-conjugated IRDye 680 in 3D tongue cancer cells stroma-enriched spheroids. Thus, IRDye-A20 could be a promising candidate for the future development of the fluorescence-guided surgery of oral cancers.CONCLUSIONSThe present study demonstrated an efficient selective targeting of A20FMDV2-conjugated IRDye 680 in 3D tongue cancer cells stroma-enriched spheroids. Thus, IRDye-A20 could be a promising candidate for the future development of the fluorescence-guided surgery of oral cancers. BackgroundIn the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infrared fluorescence guided surgery (FGS) could improve surgical resection using fluorescent probes. αVβ6 integrin has shown great potential for cancer targeting due to its overexpression in oral cancers. Red fluorescent contrast agent IRDye 680 coupled with anti-αVβ6 peptide (IRDye-A20) represents an asset to improve FGS of oral cancer. This study investigates the potential of IRDye-A20 as a selective imaging agent in 3D three-dimensional tongue cancer cells.MethodsαVβ6 integrin expression was evaluated by RT-qPCR and Western Blotting in 2D HSC-3 human tongue cancer cells and MRC-5 human fibroblasts. Targeting ability of IRDye-A20 was studied in both cell lines by flow cytometry technique. 3D tumor spheroid models, homotypic (HSC-3) and stroma-enriched heterotypic (HSC-3/MRC-5) spheroids were produced by liquid overlay procedure and further characterized using (immuno)histological and fluorescence-based techniques. IRDye-A20 selectivity was evaluated in each type of spheroids and each cell population.ResultsαVβ6 integrin was overexpressed in 2D HSC-3 cancer cells but not in MRC-5 fibroblasts and consistently, only HSC-3 were labelled with IRDye-A20. Round shaped spheroids with an average diameter of 400 μm were produced with a final ratio of 55%/45% between HSC-3 and MRC-5 cells, respectively. Immunofluorescence experiments demonstrated an uniform expression of αVβ6 integrin in homotypic spheroid, while its expression was restricted to cancer cells only in heterotypic spheroid. In stroma-enriched 3D model, Cytokeratin 19 and E-cadherin were expressed only by cancer cells while vimentin and fibronectin were expressed by fibroblasts. Using flow cytometry, we demonstrated that IRDye-A20 labeled the whole homotypic spheroid, while in the heterotypic model all cancer cells were highly fluorescent, with a negligible fluorescence in fibroblasts.ConclusionsThe present study demonstrated an efficient selective targeting of A20FMDV2-conjugated IRDye 680 in 3D tongue cancer cells stroma-enriched spheroids. Thus, IRDye-A20 could be a promising candidate for the future development of the fluorescence-guided surgery of oral cancers. In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infrared fluorescence guided surgery (FGS) could improve surgical resection using fluorescent probes. αVβ6 integrin has shown great potential for cancer targeting due to its overexpression in oral cancers. Red fluorescent contrast agent IRDye 680 coupled with anti-αVβ6 peptide (IRDye-A20) represents an asset to improve FGS of oral cancer. This study investigates the potential of IRDye-A20 as a selective imaging agent in 3D three-dimensional tongue cancer cells. αVβ6 integrin expression was evaluated by RT-qPCR and Western Blotting in 2D HSC-3 human tongue cancer cells and MRC-5 human fibroblasts. Targeting ability of IRDye-A20 was studied in both cell lines by flow cytometry technique. 3D tumor spheroid models, homotypic (HSC-3) and stroma-enriched heterotypic (HSC-3/MRC-5) spheroids were produced by liquid overlay procedure and further characterized using (immuno)histological and fluorescence-based techniques. IRDye-A20 selectivity was evaluated in each type of spheroids and each cell population. αVβ6 integrin was overexpressed in 2D HSC-3 cancer cells but not in MRC-5 fibroblasts and consistently, only HSC-3 were labelled with IRDye-A20. Round shaped spheroids with an average diameter of 400 μm were produced with a final ratio of 55%/45% between HSC-3 and MRC-5 cells, respectively. Immunofluorescence experiments demonstrated an uniform expression of αVβ6 integrin in homotypic spheroid, while its expression was restricted to cancer cells only in heterotypic spheroid. In stroma-enriched 3D model, Cytokeratin 19 and E-cadherin were expressed only by cancer cells while vimentin and fibronectin were expressed by fibroblasts. Using flow cytometry, we demonstrated that IRDye-A20 labeled the whole homotypic spheroid, while in the heterotypic model all cancer cells were highly fluorescent, with a negligible fluorescence in fibroblasts. The present study demonstrated an efficient selective targeting of A20FMDV2-conjugated IRDye 680 in 3D tongue cancer cells stroma-enriched spheroids. Thus, IRDye-A20 could be a promising candidate for the future development of the fluorescence-guided surgery of oral cancers. Abstract Background In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infrared fluorescence guided surgery (FGS) could improve surgical resection using fluorescent probes. αVβ6 integrin has shown great potential for cancer targeting due to its overexpression in oral cancers. Red fluorescent contrast agent IRDye 680 coupled with anti-αVβ6 peptide (IRDye-A20) represents an asset to improve FGS of oral cancer. This study investigates the potential of IRDye-A20 as a selective imaging agent in 3D three-dimensional tongue cancer cells. Methods αVβ6 integrin expression was evaluated by RT-qPCR and Western Blotting in 2D HSC-3 human tongue cancer cells and MRC-5 human fibroblasts. Targeting ability of IRDye-A20 was studied in both cell lines by flow cytometry technique. 3D tumor spheroid models, homotypic (HSC-3) and stroma-enriched heterotypic (HSC-3/MRC-5) spheroids were produced by liquid overlay procedure and further characterized using (immuno)histological and fluorescence-based techniques. IRDye-A20 selectivity was evaluated in each type of spheroids and each cell population. Results αVβ6 integrin was overexpressed in 2D HSC-3 cancer cells but not in MRC-5 fibroblasts and consistently, only HSC-3 were labelled with IRDye-A20. Round shaped spheroids with an average diameter of 400 μm were produced with a final ratio of 55%/45% between HSC-3 and MRC-5 cells, respectively. Immunofluorescence experiments demonstrated an uniform expression of αVβ6 integrin in homotypic spheroid, while its expression was restricted to cancer cells only in heterotypic spheroid. In stroma-enriched 3D model, Cytokeratin 19 and E-cadherin were expressed only by cancer cells while vimentin and fibronectin were expressed by fibroblasts. Using flow cytometry, we demonstrated that IRDye-A20 labeled the whole homotypic spheroid, while in the heterotypic model all cancer cells were highly fluorescent, with a negligible fluorescence in fibroblasts. Conclusions The present study demonstrated an efficient selective targeting of A20FMDV2-conjugated IRDye 680 in 3D tongue cancer cells stroma-enriched spheroids. Thus, IRDye-A20 could be a promising candidate for the future development of the fluorescence-guided surgery of oral cancers. Graphical Abstract Background: In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local recurrence and lower survival rates. Therefore, the universal goal of oral surgical oncology is to achieve microscopically clear margins. Near-infrared fluorescence guided surgery (FGS) could improve surgical resection using fluorescent probes. αVβ6 integrin has shown great potential for cancer targeting due to its overexpression in oral cancers. Red fluorescent contrast agent IRDye 680 coupled with anti-αVβ6 peptide (IRDye-A20) represents an asset to improve FGS of oral cancer. This study investigates the potential of IRDye-A20 as a selective imaging agent in 3D three-dimensional tongue cancer cells. Methods αVβ6 integrin expression was evaluated by RT-qPCR and Western Blotting in 2D HSC-3 human tongue cancer cells and MRC-5 human fibroblasts. Targeting ability of IRDye-A20 was studied in both cell lines by flow cytometry technique. 3D tumor spheroid models, homotypic (HSC-3) and stroma-enriched heterotypic (HSC-3/MRC-5) spheroids were produced by liquid overlay procedure and further characterized using (immuno)histological and fluorescence-based techniques. IRDye-A20 selectivity was evaluated in each type of spheroids and each cell population.Results: αVβ6 integrin was overexpressed in 2D HSC-3 cancer cells but not in MRC-5 fibroblasts and consistently, only HSC-3 were labelled with IRDye-A20. Round shaped spheroids with an average diameter of 400 μm were produced with a final ratio of 55%/45% between HSC-3 and MRC-5 cells, respectively. Immunofluorescence experiments demonstrated an uniform expression of αVβ6 integrin in homotypic spheroid, while its expression was restricted to cancer cells only in heterotypic spheroid. In stroma-enriched 3D model, Cytokeratin 19 and E-cadherin were expressed only by cancer cells while vimentin and fibronectin were expressed by fibroblasts. Using flow cytometry, we demonstrated that IRDye-A20 labeled the whole homotypic spheroid, while in the heterotypic model all cancer cells were highly fluorescent, with a negligible fluorescence in fibroblasts.Conclusions: The present study demonstrated an efficient selective targeting of A20FMDV2-conjugated IRDye 680 in 3D tongue cancer cells stroma-enriched spheroids. Thus, IRDye-A20 could be a promising candidate for the future development of the fluorescence-guided surgery of oral cancers. |
| ArticleNumber | 228 |
| Author | François, A Lamy, L Marchal, F Pons, T Dirheimer, L Cortese, S Bezdetnaya, L |
| Author_xml | – sequence: 1 givenname: L surname: Dirheimer fullname: Dirheimer, L organization: Centre de Recherche en Automatique de Nancy, Centre National de la Recherche Scientifique, UMR 7039, Université de Lorraine, Vandoeuvre-lès-Nancy, France – sequence: 2 givenname: T surname: Pons fullname: Pons, T organization: ESPCI Paris, LPEM UMR 8213, PSL University, CNRS, Sorbonne University, Paris, France – sequence: 3 givenname: A surname: François fullname: François, A organization: Research Department, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne, Vandoeuvre-lès-Nancy, 54519, France – sequence: 4 givenname: L surname: Lamy fullname: Lamy, L organization: Research Department, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne, Vandoeuvre-lès-Nancy, 54519, France – sequence: 5 givenname: S surname: Cortese fullname: Cortese, S organization: Surgical Department, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne, Vandoeuvre-lès-Nancy, 54519, France – sequence: 6 givenname: F surname: Marchal fullname: Marchal, F organization: Surgical Department, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne, Vandoeuvre-lès-Nancy, 54519, France – sequence: 7 givenname: L surname: Bezdetnaya fullname: Bezdetnaya, L email: L.bolotine@nancy.unicancer.fr, L.bolotine@nancy.unicancer.fr organization: Research Department, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne, Vandoeuvre-lès-Nancy, 54519, France. L.bolotine@nancy.unicancer.fr |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38951897$$D View this record in MEDLINE/PubMed https://hal.science/hal-04636463$$DView record in HAL |
| BookMark | eNpdUltrFDEYHaRiL_oHfJCAL_VhNJeZXJ6ktGoXFgSpvoZM8s1slm2yJjOF_Vn6Q_qbzHRrafsQEk7OOd-Fc1wdhBigqt4S_JEQyT9lQhVra0ybGrOGiHr3ojoijWhrKrk4ePQ-rI5zXmNMhOT4VXXIpGqJVOKo8lcmDTD6MKDYI3aBYjIbZE2wkFDeriBF7zLqduj2z6_bvxz5MMKQfEBTnkUBTKp96JNJ4NAWtqN3UNsY1tNgxgItflzsAHGJX1cve7PJ8Ob-Pql-fv1ydX5ZL79_W5yfLWvLuBzrrlWEC-OEhKYDw5RlhvG2d8YRUVDVE9EqYI1kzgnLBVPgWsdtR5wyvWUn1WLv66JZ623y1ybtdDRe3wExDdqk0dsNaGwUxlL20hpa9me7tie21MKSGQe8LV6f917bqbsGZyGMZT1PTJ_-BL_SQ7zRhFAiKabF4cPeYfVMd3m21DOGG854OTekcE_vq6X4e4I86mufLWw2JkCcsmZYNIKKpp0be_-Muo5TCmWvM0tRKriYDemeZVPMOUH_0AHBeo6Q3kdIlwjpuwjpXRG9ezzzg-R_Ztg_uVnEyA |
| Cites_doi | 10.3390/biomedicines11041058 10.1158/1078-0432.CCR-14-3284 10.1111/php.13550 10.1016/j.tranon.2020.100919 10.1016/j.neo.2022.01.001 10.1007/s11307-019-01469-5 10.1002/path.2745 10.2967/jnumed.114.150680 10.3389/fphar.2020.579068 10.1016/j.bcp.2023.115586 10.3389/fcell.2022.920303 10.1016/j.cbpa.2003.08.007 10.1016/j.ccr.2016.06.007 10.1042/BSR20180243 10.1016/j.jamcollsurg.2019.09.007 10.2174/1389201018666171004150050 10.1158/0008-5472.CAN-08-4410 10.3389/fonc.2022.1052163 10.21037/atm.2020.04.07 10.1002/smll.201701582 10.1016/j.amsu.2020.10.029 10.5535/arm.2015.39.2.210 10.1111/jop.12044 10.2147/IJN.S427350 10.1242/bio.037051 10.1080/17460441.2021.1878143 10.1158/0008-5472.CAN-18-0878 10.1002/path.2830 10.1088/2050-6120/ac1dbb 10.1016/j.pdpdt.2020.101838 10.1016/j.trecan.2018.05.009 10.3390/cancers9060056 10.1088/0022-3727/38/15/004 10.1016/S1470-2045(19)30317-1 10.4103/1735-3327.250974 10.1016/j.oraloncology.2013.11.001 10.3390/cancers12061474 10.1038/s41598-021-03134-w 10.1007/s00441-005-0148-2 10.2147/IJN.S146927 10.5732/cjc.012.10219 10.1007/s00441-016-2474-y 10.1038/srep39805 10.1186/s12957-020-01874-z 10.1038/srep10169 10.3390/jpm13111575 10.1016/j.neo.2017.05.002 10.1097/01.PRS.0000131872.90767.50 10.1016/j.jbc.2021.100657 10.1111/j.1600-0714.2005.00374.x 10.1002/jcb.26642 10.1002/hed.21166 10.1158/0008-5472.CAN-07-1026 10.1083/jcb.201102147 10.1006/bbrc.2001.5813 10.1021/acsnano.8b03900 10.1038/s41392-022-00904-4 10.1117/1.JBO.26.5.050901 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License The Author(s) 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License – notice: The Author(s) 2024 |
| DBID | NPM AAYXX CITATION 3V. 7TM 7TO 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 1XC 5PM DOA |
| DOI | 10.1186/s12935-024-03417-y |
| DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest Central Essentials ProQuest One Academic Eastern Edition Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1475-2867 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_0a90088f8ca2417cb5f1c65f083ade65 oai_HAL_hal_04636463v1 10_1186_s12935_024_03417_y 38951897 |
| Genre | Journal Article |
| GeographicLocations | United Kingdom--UK France United States--US Germany |
| GeographicLocations_xml | – name: Germany – name: United Kingdom--UK – name: France – name: United States--US |
| GroupedDBID | --- -56 -5G -A0 -BR 0R~ 29B 2WC 3V. 53G 5GY 5VS 6J9 7X7 8FI 8FJ AAFWJ AAJSJ ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FRP FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR ISR ITC KQ8 LGEZI LOTEE M~E NADUK NPM NXXTH O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M AAYXX CITATION 7TM 7TO 7XB 8FK AZQEC DWQXO H94 K9. M48 PQEST PQUKI PRINS 7X8 1XC 5PM |
| ID | FETCH-LOGICAL-c368t-b59167ad78e4bea39c3a365fdad17d789f1759e3483dd7c6739ed5d6cb1d9afc3 |
| IEDL.DBID | RPM |
| ISSN | 1475-2867 |
| IngestDate | Tue Oct 22 15:12:12 EDT 2024 Tue Sep 17 21:28:30 EDT 2024 Tue Oct 15 14:56:05 EDT 2024 Sat Oct 26 04:49:56 EDT 2024 Thu Oct 10 22:53:16 EDT 2024 Fri Nov 22 03:09:30 EST 2024 Sat Nov 02 11:57:05 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Fluorescence imaging Oral cancer Near Infrared fluorescence (NIR) αVβ6 integrin Head and neck cancer Tongue cancer Spheroid IRDye |
| Language | English |
| License | 2024. The Author(s). Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c368t-b59167ad78e4bea39c3a365fdad17d789f1759e3483dd7c6739ed5d6cb1d9afc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-2607-4652 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218202/ |
| PMID | 38951897 |
| PQID | 3079227671 |
| PQPubID | 42567 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0a90088f8ca2417cb5f1c65f083ade65 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11218202 hal_primary_oai_HAL_hal_04636463v1 proquest_miscellaneous_3074727455 proquest_journals_3079227671 crossref_primary_10_1186_s12935_024_03417_y pubmed_primary_38951897 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-06-29 |
| PublicationDateYYYYMMDD | 2024-06-29 |
| PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Cancer cell international |
| PublicationTitleAlternate | Cancer Cell Int |
| PublicationYear | 2024 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | 3417_CR42 EM Tosca (3417_CR32) 2023; 11 G Nicoletti (3417_CR7) 2004; 114 3417_CR45 3417_CR48 GJ Thomas (3417_CR21) 2006; 35 RZ Lin (3417_CR49) 2006; 324 A Francois (3417_CR34) 2023; 18 N Tajmirriahi (3417_CR2) 2019; 16 S Gupta (3417_CR3) 2021; 14 A Saha (3417_CR46) 2010; 222 SH Hausner (3417_CR63) 2015; 56 3417_CR33 VM Baart (3417_CR22) 2020; 12 AN Bashkatov (3417_CR57) 2005; 38 P Lu (3417_CR50) 2012; 196 D Marsh (3417_CR25) 2011; 223 3417_CR39 L Wang (3417_CR60) 2022; 7 H Xue (3417_CR23) 2001; 288 CW Barth (3417_CR53) 2020; 18 3417_CR37 3417_CR36 II Cardle (3417_CR27) 2021; 296 SH Hausner (3417_CR28) 2007; 67 JR Hsiao (3417_CR47) 2010; 32 L Bodner (3417_CR6) 2014; 50 RW Gao (3417_CR12) 2018; 78 C Lee (3417_CR38) 2014; 34 3417_CR9 M Xu (3417_CR43) 2018; 119 J Dardare (3417_CR44) 2022; 12 SH Hausner (3417_CR30) 2009; 69 JV Frangioni (3417_CR54) 2003; 7 3417_CR29 DS Chandrashekar (3417_CR41) 2022; 25 3417_CR26 Q Dai (3417_CR51) 2018; 12 S Hernot (3417_CR52) 2019; 20 M Millard (3417_CR59) 2017; 12 YR Son (3417_CR8) 2015; 39 Y Cui (3417_CR58) 2017; 18 DS Chandrashekar (3417_CR40) 2017; 19 3417_CR1 HX Li (3417_CR20) 2013; 42 HS Rehmani (3417_CR14) 2020; 8 Z Khan (3417_CR24) 2016; 365 3417_CR11 3417_CR55 S van Keulen (3417_CR13) 2019; 229 T Ganguly (3417_CR31) 2020; 22 SB Ravi (3417_CR61) 2014; 8 B Wang (3417_CR5) 2013; 32 3417_CR19 3417_CR18 3417_CR15 JM Dąbrowski (3417_CR56) 2016; 325 O Elaiwy (3417_CR4) 2020; 60 J Pan (3417_CR10) 2020; 18 I Arutyunyan (3417_CR35) 2023; 13 EL Rosenthal (3417_CR16) 2015; 21 L Finlayson (3417_CR62) 2022; 98 G Marsico (3417_CR17) 2018; 4 |
| References_xml | – volume: 11 start-page: 1058 issue: 4 year: 2023 ident: 3417_CR32 publication-title: Biomedicines doi: 10.3390/biomedicines11041058 contributor: fullname: EM Tosca – volume: 21 start-page: 3658 year: 2015 ident: 3417_CR16 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-3284 contributor: fullname: EL Rosenthal – volume: 98 start-page: 974 year: 2022 ident: 3417_CR62 publication-title: Photochem Photobiol doi: 10.1111/php.13550 contributor: fullname: L Finlayson – volume: 14 start-page: 100919 year: 2021 ident: 3417_CR3 publication-title: Transl Oncol doi: 10.1016/j.tranon.2020.100919 contributor: fullname: S Gupta – volume: 25 start-page: 18 year: 2022 ident: 3417_CR41 publication-title: Neoplasia doi: 10.1016/j.neo.2022.01.001 contributor: fullname: DS Chandrashekar – volume: 22 start-page: 1170 year: 2020 ident: 3417_CR31 publication-title: Mol Imaging Biol doi: 10.1007/s11307-019-01469-5 contributor: fullname: T Ganguly – volume: 222 start-page: 52 year: 2010 ident: 3417_CR46 publication-title: J Pathol doi: 10.1002/path.2745 contributor: fullname: A Saha – volume: 56 start-page: 784 year: 2015 ident: 3417_CR63 publication-title: J Nucl Med doi: 10.2967/jnumed.114.150680 contributor: fullname: SH Hausner – ident: 3417_CR19 doi: 10.3389/fphar.2020.579068 – ident: 3417_CR33 doi: 10.1016/j.bcp.2023.115586 – ident: 3417_CR45 doi: 10.3389/fcell.2022.920303 – volume: 7 start-page: 626 year: 2003 ident: 3417_CR54 publication-title: Curr Opin Chem Biol Elsevier Ltd doi: 10.1016/j.cbpa.2003.08.007 contributor: fullname: JV Frangioni – volume: 325 start-page: 67 year: 2016 ident: 3417_CR56 publication-title: Coord Chem Rev Elsevier B V doi: 10.1016/j.ccr.2016.06.007 contributor: fullname: JM Dąbrowski – ident: 3417_CR42 doi: 10.1042/BSR20180243 – volume: 229 start-page: 560 year: 2019 ident: 3417_CR13 publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2019.09.007 contributor: fullname: S van Keulen – volume: 18 start-page: 669 year: 2017 ident: 3417_CR58 publication-title: Curr Pharm Biotechnol doi: 10.2174/1389201018666171004150050 contributor: fullname: Y Cui – volume: 69 start-page: 5843 year: 2009 ident: 3417_CR30 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-4410 contributor: fullname: SH Hausner – volume: 34 start-page: 6945 year: 2014 ident: 3417_CR38 publication-title: Anticancer Res contributor: fullname: C Lee – volume: 12 start-page: 1052163 year: 2022 ident: 3417_CR44 publication-title: Front Oncol doi: 10.3389/fonc.2022.1052163 contributor: fullname: J Dardare – volume: 8 start-page: 813 year: 2020 ident: 3417_CR14 publication-title: Ann Transl Med doi: 10.21037/atm.2020.04.07 contributor: fullname: HS Rehmani – ident: 3417_CR39 doi: 10.1002/smll.201701582 – volume: 60 start-page: 195 year: 2020 ident: 3417_CR4 publication-title: Ann Med Surg (London) doi: 10.1016/j.amsu.2020.10.029 contributor: fullname: O Elaiwy – volume: 39 start-page: 210 year: 2015 ident: 3417_CR8 publication-title: Ann Rehabil Med doi: 10.5535/arm.2015.39.2.210 contributor: fullname: YR Son – volume: 42 start-page: 547 year: 2013 ident: 3417_CR20 publication-title: J Oral Pathol Med doi: 10.1111/jop.12044 contributor: fullname: HX Li – volume: 18 start-page: 6545 year: 2023 ident: 3417_CR34 publication-title: Int J Nanomed doi: 10.2147/IJN.S427350 contributor: fullname: A Francois – ident: 3417_CR48 doi: 10.1242/bio.037051 – ident: 3417_CR29 doi: 10.1080/17460441.2021.1878143 – volume: 78 start-page: 5144 year: 2018 ident: 3417_CR12 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-18-0878 contributor: fullname: RW Gao – volume: 223 start-page: 470 year: 2011 ident: 3417_CR25 publication-title: J Pathol doi: 10.1002/path.2830 contributor: fullname: D Marsh – ident: 3417_CR55 doi: 10.1088/2050-6120/ac1dbb – ident: 3417_CR11 doi: 10.1016/j.pdpdt.2020.101838 – volume: 4 start-page: 537 issue: 8 year: 2018 ident: 3417_CR17 publication-title: Trends Cancer Cell Press doi: 10.1016/j.trecan.2018.05.009 contributor: fullname: G Marsico – ident: 3417_CR18 doi: 10.3390/cancers9060056 – volume: 38 start-page: 2543 year: 2005 ident: 3417_CR57 publication-title: J Phys D Appl Phys doi: 10.1088/0022-3727/38/15/004 contributor: fullname: AN Bashkatov – volume: 20 start-page: 354 year: 2019 ident: 3417_CR52 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30317-1 contributor: fullname: S Hernot – volume: 16 start-page: 117 year: 2019 ident: 3417_CR2 publication-title: Dent Res J (Isfahan) doi: 10.4103/1735-3327.250974 contributor: fullname: N Tajmirriahi – volume: 50 start-page: 84 year: 2014 ident: 3417_CR6 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2013.11.001 contributor: fullname: L Bodner – volume: 12 start-page: 1474 year: 2020 ident: 3417_CR22 publication-title: Cancers (Basel) doi: 10.3390/cancers12061474 contributor: fullname: VM Baart – ident: 3417_CR36 doi: 10.1038/s41598-021-03134-w – volume: 324 start-page: 411 year: 2006 ident: 3417_CR49 publication-title: Cell Tissue Res doi: 10.1007/s00441-005-0148-2 contributor: fullname: RZ Lin – ident: 3417_CR37 – volume: 12 start-page: 7993 year: 2017 ident: 3417_CR59 publication-title: Int J Nanomed doi: 10.2147/IJN.S146927 contributor: fullname: M Millard – volume: 32 start-page: 614 year: 2013 ident: 3417_CR5 publication-title: Chin J Cancer doi: 10.5732/cjc.012.10219 contributor: fullname: B Wang – volume: 365 start-page: 657 year: 2016 ident: 3417_CR24 publication-title: Cell Tissue Res Springer Verlag doi: 10.1007/s00441-016-2474-y contributor: fullname: Z Khan – ident: 3417_CR26 doi: 10.1038/srep39805 – volume: 18 start-page: 96 year: 2020 ident: 3417_CR10 publication-title: World J Surg Oncol doi: 10.1186/s12957-020-01874-z contributor: fullname: J Pan – ident: 3417_CR15 doi: 10.1038/srep10169 – volume: 18 start-page: 11222 year: 2020 ident: 3417_CR53 publication-title: SPIE-Intl Soc Opt Eng contributor: fullname: CW Barth – volume: 13 start-page: 1575 year: 2023 ident: 3417_CR35 publication-title: J Pers Med doi: 10.3390/jpm13111575 contributor: fullname: I Arutyunyan – ident: 3417_CR1 – volume: 19 start-page: 649 year: 2017 ident: 3417_CR40 publication-title: Neoplasia doi: 10.1016/j.neo.2017.05.002 contributor: fullname: DS Chandrashekar – volume: 8 start-page: ZE01 issue: 9 year: 2014 ident: 3417_CR61 publication-title: J Clin Diagn contributor: fullname: SB Ravi – volume: 114 start-page: 329 year: 2004 ident: 3417_CR7 publication-title: Plast Reconstr Surg doi: 10.1097/01.PRS.0000131872.90767.50 contributor: fullname: G Nicoletti – volume: 296 start-page: 100657 year: 2021 ident: 3417_CR27 publication-title: J Biol Chem doi: 10.1016/j.jbc.2021.100657 contributor: fullname: II Cardle – volume: 35 start-page: 1 year: 2006 ident: 3417_CR21 publication-title: J Oral Pathol Med doi: 10.1111/j.1600-0714.2005.00374.x contributor: fullname: GJ Thomas – volume: 119 start-page: 4193 year: 2018 ident: 3417_CR43 publication-title: J Cell Biochem doi: 10.1002/jcb.26642 contributor: fullname: M Xu – volume: 32 start-page: 160 year: 2010 ident: 3417_CR47 publication-title: Head Neck doi: 10.1002/hed.21166 contributor: fullname: JR Hsiao – volume: 67 start-page: 7833 year: 2007 ident: 3417_CR28 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-1026 contributor: fullname: SH Hausner – volume: 196 start-page: 395 issue: 4 year: 2012 ident: 3417_CR50 publication-title: J Cell Biol doi: 10.1083/jcb.201102147 contributor: fullname: P Lu – volume: 288 start-page: 610 year: 2001 ident: 3417_CR23 publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.2001.5813 contributor: fullname: H Xue – volume: 12 start-page: 8423 year: 2018 ident: 3417_CR51 publication-title: ACS Nano doi: 10.1021/acsnano.8b03900 contributor: fullname: Q Dai – volume: 7 start-page: 48 year: 2022 ident: 3417_CR60 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-022-00904-4 contributor: fullname: L Wang – ident: 3417_CR9 doi: 10.1117/1.JBO.26.5.050901 |
| SSID | ssj0017860 |
| Score | 2.400018 |
| Snippet | In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher local... BackgroundIn the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher... Background: In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with higher... Abstract Background In the treatment of oral cavity cancer, margin status is one of the most critical prognostic factors. Positive margins are associated with... |
| SourceID | doaj pubmedcentral hal proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 228 |
| SubjectTerms | Amino acids Antibodies Cancer Cell culture Cells Contrast media Cytokeratin E-cadherin Extracellular matrix Fibroblasts Fibronectin Flow cytometry Fluorescence Fluorescence imaging Fluorescent indicators Head & neck cancer Head and neck cancer Heat I.R. radiation Immunofluorescence Life Sciences Microscopy Nanoparticles Oncology Oral cancer Oral carcinoma Oral cavity Peptides Polymers Spheroid Spheroids Squamous cell carcinoma Stroma Surgery Tongue Tongue cancer Tumor cell lines Tumors Vimentin Western blotting αVβ6 integrin |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLWgEhIbxJtAiwxih6wmcfxalk6rQUIsoCB2lp90WCTVpIOUz6If0m_qtZMZEViwYZGNHcXWvce-x871MUJvWFpVCB6IEyqSxntGVG0tKaMTUdkAESNtDSw_i4_f5OIkyeTsrvpKOWGjPPBouMPSKAhTMkpnINgIZ1msHGcRqIPxgY_qpaXYLqam_wdC8nJ7REbywz5FtXQSuSElTNuCDLMwlNX6Ibicp1zIv4nmn_mSvwWg0_vo3sQc8dHY4wfoVmgfojvjXZLDI7Q6yzndEIlwFzFd4HT0Hrvk1DXuk3hAt_I9tgO-_vX1-orjUShi1eKU-v4dtwB5AnBbp4x0fJGSXTzYtmt_bNJOm8fvPy2GgLksH6Mvpydnx0sy3aNAHOXyklgGHFAYL2RobDBUOWoomNAbXwkoVRE4hAq0kdR74bigKnjmubOVVyY6-gTttV0bniHotYzOAqWhNjSRK1Mb7kpXBsZkxVxdoLdbs-qLUS5D52WG5Hp0ggYn6OwEPRToXbL87s0kdZ0LAAB6AoD-FwAK9Br8NvvG8uiDTmVZDQ2en1WB9rdu1dMg7TVMb6quBRdQ_WpXDcMr_TMxbeg2-Z0GKF7DoJ2nIwp2TQHXY5VUokByho9ZX-Y17eo8S3gDy03K-fXz_2GBF-hunaHNSa320d7lehMO0O3eb17mUXEDBOUSUg priority: 102 providerName: Directory of Open Access Journals |
| Title | Targeting of 3D oral cancer spheroids by αVβ6 integrin using near-infrared peptide-conjugated IRDye 680 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38951897 https://www.proquest.com/docview/3079227671 https://www.proquest.com/docview/3074727455 https://hal.science/hal-04636463 https://pubmed.ncbi.nlm.nih.gov/PMC11218202 https://doaj.org/article/0a90088f8ca2417cb5f1c65f083ade65 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbhMxFLVIJVA3iHcDJTKIHXIzL7-WpWmViocQFMTO8rMNojNR0iDNZ8GH9Ju49mSiBnYsZmN7Zizfa99j-_gYoVc0zio488RyGUjlHCWyMIZkwfIgjYeIEZcGpp_5h29ichxlclh_FiaR9q2ZHdQ_Lg_q2UXiVs4v7bjniY0_vj8CjBB1x4vxAA0AHPZz9PXeARcs64_HCDZexogWTyFXJIMhm5N2F92BME1zEZWebkSjJNoPMeYiUiL_xZt_0yZvxKGTe-juGkDiw66i99EtXz9At7srJduHaHaWqN0QkHATcDnB8QQ-ttG2C7yMGgLNzC2xafH1r6_Xvxnu9CJmNY4M-HNcg-cT8LpFJKbjeeS8OGjipv6-igtuDp9-mrQeM5E9Ql9Ojs-OpmR9nQKxJRNXxFCAglw7LnxlvC6lLXXJaHDa5RxSZQAoIX1ZidI5bhkvpXfUMWtyJ3Ww5WO0Uze130NQaxGsAWRTGl8FJnWhmc1s5ikVObXFEL3um1XNO9UMlWYbgqnOHgrsoZI9VDtEb2LLb0pGxeuU0CzO1druKtMS4IoIwmoAHdwaGnILtQcIqZ1ndIhegt22vjE9fKdiWhJFg-dnPkT7vVnVuq8uFYxysig445D9YpMNvSxunejaN6tUpgKkV1H4z5POCza_6n1piMSWf2zVZTsHHDspefeO_PT_X32Gdovk24wUch_tXC1W_jkaLN1qBDOE07ejtMowSl3kD4z4FP8 |
| link.rule.ids | 230,315,729,782,786,866,887,2107,27934,27935,53802,53804 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbhMxFLVoEdAN70eggEHskJt5-bUsTatUpBWCgNhZfrZBdCZKGqR8FnxIv4lrT6ZqYNfFbOx5eObe63vsOT5G6B2NowrOPLFcBlI5R4ksjCFZsDxI4yFjxKmB4Rd-_F0M9qNMDuvWwiTSvjWTnfrn2U49OU3cyumZ7Xc8sf6noz3ACFF3vOhvoJsQsFnRjdJXfw-4YFm3QEaw_jzmtLgOuSIZdNqcLLfQbUjUNBdR6-lKPkqy_ZBlTiMp8n_E-S9x8komOrh33Xe4j-6usCfebesfoBu-fohutbtRLh-hyTixwiGX4SbgcoDj4n1so1vM8DzKDzQTN8dmiS9-f7v4w3ArNTGpcSTPn-AagoaAw84ipx1PI13GgXWa-sciztU5fPh5sPSYiewx-nqwP94bktVODMSWTJwTQwFFcu248JXxupS21CWjwWmXcyiVAVCI9GUlSue4ZbyU3lHHrMmd1MGWT9Bm3dT-GYJWi2ANgKLS-CowqQvNbGYzT6nIqS166H1nDzVtBTdUGqgIplpDKjCkSoZUyx76EE12eWYUy04FzexErT63yrQEpCOCsBrwCreGhtxC6wF9aucZ7aG3YPC1ewx3RyqWJT01OH7lPbTd-YNahflcQQcpi4IzDtVvLqshQONfF137ZpHOqQAkVhSe87R1n8tHdU7YQ2LNsdbasl4D_pREwDv_eX79S1-jO8Px0UiNDo8_vkBbRQoQRgq5jTbPZwv_Em3M3eJViq2_s2UovQ |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LbtQwFLVoEVU3vAsDBQxih9zJyy92pdNRK0pVQUHsLD_bQTQZzXSQ5rPgQ_pNXDuTUQd2sMjGdhIn917f4-T4GKHXNM4qOPPEchlI5RwlsjCGZMHyII2HjBE_DRx84sdfxWA_yuS87dbCJNK-NaOd-vvFTj06T9zK8YXtdzyx_smHPcAIUXe86I9d6K-hmxC0WdXN1Bd_ELhgWbdIRrD-NOa1uBa5IhkM3JzMN9EGJGuai6j3dC0nJel-yDTnkRj5N-r8kzx5LRsN7_zPc9xFtxcYFO-2be6hG76-j261u1LOH6DRaWKHQ07DTcDlAMdF_NhG95jgaZQhaEZuis0cX_38cvWL4VZyYlTjSKI_wzUEDwHHnURuOx5H2owDKzX1t1n8Zufw4cfB3GMmsofo83D_dO-ALHZkILZk4pIYCmiSa8eFr4zXpbSlLhkNTrucQ6kMgEakLytROsct46X0jjpmTe6kDrbcQut1U_vHCHotgjUAjkrjq8CkLjSzmc08pSKntuihN51N1LgV3lBpwiKYao2pwJgqGVPNe-hdNNuyZRTNTgXN5EwtXrnKtATEI4KwGnALt4aG3ELvAYVq5xntoVdg9JVrHOweqViWdNXg-JH30HbnE2oR7lMFA6UsCs44VL9cVkOgxr8vuvbNLLWpACxWFO7zqHWh5a06R-whseJcK31ZrQGfSmLgnQ89-fdTX6CNk8FQHR0ev3-KNosUI4wUchutX05m_hlam7rZ8xRevwH5rCs9 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+of+3D+oral+cancer+spheroids+by+%CE%B1V%CE%B26+integrin+using+near-infrared+peptide-conjugated+IRDye+680&rft.jtitle=Cancer+cell+international&rft.au=Dirheimer%2C+L&rft.au=Pons%2C+T&rft.au=Fran%C3%A7ois%2C+A&rft.au=Lamy%2C+L&rft.date=2024-06-29&rft.pub=BioMed+Central&rft.eissn=1475-2867&rft.volume=24&rft.spage=1&rft_id=info:doi/10.1186%2Fs12935-024-03417-y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon |